Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Baseline characteristics at inclusion, median values (range)

From: Early increase in serum-COMP is associated with joint damage progression over the first five years in patients with rheumatoid arthritis

  Group UnCh (N=142) Group InCr (N=34) Group DeCr (N=173) All (N=349) P-value*
Age 58 (16–83) 56 (25–83) 57 (18–84) 58 (16–84) 0.96
Gender (% women) 62 56 68 64 0.33**
Disease duration (months) 6.0 (1–13) 3.5 (1–12) 6.0 (1–21) 6,0 (1–21) 0.10
DAS28 5.4 (0.5-7.9) 5.5 (0.5-8.0) 5.1 (2.3-8.1) 5,3 (0,5-8,1) 0.06
HAQ 0.9 (0–2.6) 1.3 (0–2.3) 0.9 (0–2.5) 0,9 (0–2,6) 0.10
ESR (mm/H) 33 (2–110) 42 (2–140) 27 (2–115) 31 (2–140) 0.006
CRP (mg/L) 22.0 (4–186) 29.5 (3–159) 19.0 (4–228) 21 (3–228) 0.40
RF positive (%) 61 67 56 59 0.46**
Anti-CCP (%) 58 61 56 57 0.86**
COMP (U/L) 11.9 (6.1-26.8) 9.6 (5.6-19.3) 13.8 (4.5-32.0) 12.7 (4.5-32.0) <0.001
Erosion score 0 (0–44) 0 (0–20) 0 (0–15) 0 (0–44) 0.68
JSN score 0 (0–40) 0 (0–15) 0 (0–33) 0 (0–40) 0.41
Total Sharp score 1 (0–84) 2 (0–34) 0.25 (0–35) 1 (0–84) 0.52
  1. Group UnCh, patients with unchanged serum-COMP levels from inclusion to 3 months follow-up (change ≤ 20%),
  2. Group InCr, increasing serum- COMP levels from inclusion to 3 months follow-up (increase > 20%).
  3. Group DeCr, decreasing serum-COMP levels from inclusion to 3 months follow-up (decrease > 20%).
  4. *Kruskal-Wallis test, ** Chi2 test.